- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
- 个人中心
- 退出登录
浏览全部资源
扫码关注微信
- Journal Information
- Journal Introduction
- Editorial Board
- Youth Editorial Board
- Editorial Board Charter
- Subscriptions
- Archive
- Current Issue
- Past Issues
- Priority Publication
- Virtual Collection
- Recommended Articles
- Submission
- Submission Process
- Submission Guidelines
- Download
- Contact us
- For Reviewers
- Guidelines for Reviewers
- Peer Reviewed Policies
- Statement and Policies
- Ethics and Malpractice
- Research Ethics Policies
- Repetition Detection
- Corrections and Retractions
- Editorial Policies
- Open Access Statement
- Website Responsibility
Mining and analysis of ADE signals of two camptothecin topoisomerase 1 inhibitors
- ZHONGGUO YAOFANG Vol. 35, Issue 9, Pages: 1133-1138(2024)
- 作者机构：
1.川北医学院临床医学院，四川 南充 637000
2.川北医学院附属医院胃肠外科，四川 南充 637000
3.川北医学院附属医院重症医学科，四川 南充 637000
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2024.09.19
CLC： R969.3;R979.1Received：15 September 2023，
Revised：2024-04-12，
Accepted：12 April 2024，
Published：15 May 2024
- 稿件说明：
移动端阅览
吴镇江,刘建军,白翔宇,等.2种喜树碱类拓扑异构酶1抑制剂ADE信号的挖掘与分析[J].中国药房,2024,35(09):1133-1138.
WU Zhenjiang,LIU Jianjun,BAI Xiangyu,et al.Mining and analysis of ADE signals of two camptothecin topoisomerase 1 inhibitors[J].ZHONGGUO YAOFANG,2024,35(09):1133-1138.
吴镇江,刘建军,白翔宇,等.2种喜树碱类拓扑异构酶1抑制剂ADE信号的挖掘与分析[J].中国药房,2024,35(09):1133-1138. DOI： 10.6039/j.issn.1001-0408.2024.09.19.
WU Zhenjiang,LIU Jianjun,BAI Xiangyu,et al.Mining and analysis of ADE signals of two camptothecin topoisomerase 1 inhibitors[J].ZHONGGUO YAOFANG,2024,35(09):1133-1138. DOI： 10.6039/j.issn.1001-0408.2024.09.19.
摘要
目的
2
对2种喜树碱类拓扑异构酶1抑制剂伊立替康和托泊替康的药物不良事件（ADE）信号进行挖掘与分析，为临床安全用药提供参考。
方法
2
基于美国FDA不良事件报告系统（FAERS）数据库，提取2004年1月1日至2023年3月31日上述2种药物的ADE报告数据。对数据进行处理后，采用报告比值比法联合贝叶斯置信传播神经网络法进行信号挖掘，并进行分析。
结果
2
共筛选出相关ADE报告14 738份，其中伊立替康11 483份，托泊替康3 255份。伊立替康的ADE报告性别以男性为主，托泊替康以女性为主；两药的使用患者年龄均主要集中于45～＜75岁。共检测出847个信号，累及24个系统器官分类（SOC）。其中，伊立替康检测出565个信号，累及24个SOC，主要集中于胃肠系统疾病、全身性疾病及给药部位各种反应、血液及淋巴系统疾病等；报告频数最多的ADE为腹泻，信号强度最大的ADE为胆碱能综合征。托泊替康检测出282个信号，累及22个SOC，主要集中于全身性疾病及给药部位各种反应、各类检查、血液及淋巴系统疾病、胃肠系统疾病等；报告频数较多的ADE为死亡和贫血，信号强度最大的ADE为发热性骨髓再生障碍。伊立替康的转移性结肠直肠癌、外周感觉神经病、脂肪性肝炎等ADE和托泊替康的虹膜萎缩、视网膜变性、玻璃体积血等ADE均未在各自说明书中提及。
结论
2
伊立替康和托泊替康的ADE主要累及消化系统和血液系统，临床上应重点监测；伊立替康所引起的胆碱能综合征应引起关注。除此之外，使用伊立替康的患者还应关注转移性结肠直肠癌、外周感觉神经病、脂肪性肝炎、蛋白尿等ADE，使用托泊替康的患者应加强眼器官疾病的监测，以确保用药安全。
Abstract
OBJECTIVE
2
To mine and analyze the adverse drug events （ADE） signals of two camptothecin topoisomerase 1 inhibitors， i.e. irinotecan and topotecan， and to provide reference for clinical medication safety.
METHODS
2
Based on the U.S. Food and Drug Administration Adverse Event Reporting System （FAERS） database， ADE report data for the aforementioned two drugs were extracted from January 1， 2004 to March 31， 2023. After processing the data， signal mining was conducted by using the reporting odds ratio in conjunction with the Bayesian confidence propagation neural network， followed by analysis.
RESULTS
2
A total of 14 738 relevant ADE reports were screened， among which 11 483 were associated with irinotecan and 3 255 with topotecan. The ADE reports for irinotecan were predominantly male， whereas for topotecan， they were predominantly female； the age of patients using the two drugs mainly concentrated in 45-＜75 years old. A total of 847 signals were detected， involving 24 system organ classes （SOCs）. Among them， 565 signals of irinotecan were detected， involving 24 SOCs， primarily concentrating on gastrointestinal disorders， general disorders and administration site conditions， blood and lymphatic system disorders； the most frequently reported ADE was diarrhea， and the ADE with the strongest signal intensity was cholinergic syndrome. A total of 282 signals of topotecan were detected， involving 22 SOCs， primarily concentrating on general disorders and administration site conditions， investigations， blood and lymphatic system disorders， and gastrointestinal disorders； the most frequently reported ADEs were death and anemia， and the ADE with the strongest signal intensity was febrile bone marrow aplasia. ADE signals for irinotecan such as metastatic colorectal cancer， peripheral sensory neuropathy， steatohepatitis， and those for topotecan such as iris atrophy， retinal degeneration， vitreous hemorrhage， were not documented in their respective drug instruction.
CONCLUSIONS
2
ADEs of irinotecan and topotecan primarily involve the digestive and hematologic systems， warranting close clinical monitoring. Cholinergic syndrome caused by irinotecan should be concerned. In addition， patients receiving irinotecan should also be monitored for ADE such as metastatic colorectal cancer， peripheral sensory neuropathy， steatohepatitis， and proteinuria； for patients using topotecan， enhanced surveillance of ocular diseases is recommended to ensure medication safety.
关键词
Keywords
references
BAILLY C . Irinotecan：25 years of cancer treatment [J ] . Pharmacol Res ， 2019 ， 148 ： 104398 .
THOMAS A ， POMMIER Y . Targeting topoisomerase Ⅰ in the era of precision medicine [J ] . Clin Cancer Res ， 2019 ， 25 （ 22 ）： 6581 - 6589 .
冯庆梅 ， 陈刚 ， 裴月湖 . DNA拓扑异构酶Ⅰ抑制剂的研究进展 [J ] . 沈阳药科大学学报 ， 2015 ， 32 （ 11 ）： 900 - 910 .
FENG Q M ， CHEN G ， PEI Y H . Recent research progress in DNA topoisomerase Ⅰ inhibitors [J ] . J Shenyang Pharm Univ ， 2015 ， 32 （ 11 ）： 900 - 910 .
ALSHAMMARI M K ， ALGHAZWNI M K ， ALHARBI A S ， et al . Nanoplatform for the delivery of topotecan in the cancer milieu：an appraisal of its therapeutic efficacy [J ] . Cancers ， 2022 ， 15 （ 1 ）： 65 .
MIELE L ， LIGUORI A ， MARRONE G ， et al . Fatty liver and drugs：the two sides of the same coin [J ] . Eur Rev Med Pharmacol Sci ， 2017 ， 21 （ 1 Suppl ）： 86 - 94 .
BOILÈVE A ， JOZWIAK M ， MALKA D ， et al . Vision loss after chemotherapy：an irinotecan-induced retinopathy [J ] . Eur J Cancer ， 2019 ， 112 ： 80 - 82 .
ZHEN D B ， MCDEVITT R L ， ZALUPSKI M M ， et al . Irinotecan-associated dysarthria：a single institution case series with management implications in patients with ga- strointestinal malignancies [J ] . J Oncol Pharm Pract ， 2019 ， 25 （ 4 ）： 980 - 986 .
GUAN Y Y ， JI L ， ZHENG L ， et al . Development of a drug risk analysis and assessment system and its application in signal excavation and analysis of 263 cases of fluoroquinolone-induced adverse reactions [J ] . Front Pharmacol ， 2022 ， 13 ： 892503 .
BATE A ， LINDQUIST M ， EDWARDS I R ， et al . A Bayesian neural network method for adverse drug reaction signal generation [J ] . Eur J Clin Pharmacol ， 1998 ， 54 （ 4 ）： 315 - 321 .
KUIPERS E J ， GRADY W M ， LIEBERMAN D ， et al . Colorectal cancer [J ] . Nat Rev Dis Primers ， 2015 ， 1 ： 15065 .
GANTI A K P ， LOO B W ， BASSETTI M ， et al . Small cell lung cancer，version 2.2022，NCCN clinical practice guidelines in oncology [J ] . J Natl Compr Canc Netw ， 2021 ， 19 （ 12 ）： 1441 - 1464 .
Pharmacia & Upjohn Co Division of Pfizer Inc . Highlights of prescribing information [EB/OL ] . （ 2022-01-27 ）[ 2024-04-11 ] . https：//www.accessdata.fda.gov/drugsatfda_ docs/label/2022/020571Orig1s053lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020571Orig1s053lbl.pdf .
Teva Pharmaceuticals USA ， Inc . Highlights of prescribing information [EB/OL ] . [ 2024-04-11 ] . https：//www.accessdata.fda.gov/drugsatfda_docs/label/2019/022453s011lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022453s011lbl.pdf .
刘慧龙 ， 李志宇 ， 刘彦芳 ， 等 . 伊立替康治疗结直肠癌相关胆碱能综合征89例 [J ] . 世界华人消化杂志 ， 2012 ， 20 （ 11 ）： 975 - 979 .
LIU H L ， LI Z Y ， LIU Y F ， et al . Irinotecan-related choli- nergic symptoms in patients with colorectal cancer patients：an analysis of 89 cases [J ] . China Ind Econ ， 2012 ， 20 （ 11 ）： 975 - 979 .
冯蕾 ， 孙谦 ， 姜开杰 ， 等 . 伊立替康致过敏反应及急性胆碱能综合征患者的用药监护 [J ] . 实用医药杂志 ， 2018 ， 35 （ 11 ）： 1021 - 1025 .
FENG L ， SUN Q ， JIANG K J ， et al . Pharmaceutical monitoring of a patient with anaphylaxis and acute cholinergic syndrome caused by irinotecan [J ] . Pract J Med Pharm ， 2018 ， 35 （ 11 ）： 1021 - 1025 .
屠文莲 ， 张志清 ， 曹玮 . 伊立替康致老年结肠癌患者急性胆碱能综合征1例 [J ] . 中国医院用药评价与分析 ， 2016 ， 16 （ 2 ）： 288 .
TU W L ， ZHANG Z Q ， CAO W . A case of acute cholinergic syndrome caused by irinotecan in elderly patients with colon cancer [J ] . Eval Anal Drug Use Hosp China ， 2016 ， 16 （ 2 ）： 288 .
MORTON C L ， WADKINS R M ， DANKS M K ， et al . The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase [J ] . Cancer Res ， 1999 ， 59 （ 7 ）： 1458 - 1463 .
KANBAYASHI Y ， ISHIKAWA T ， KANAZAWA M ， et al . Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis [J ] . Med Oncol ， 2018 ， 35 （ 6 ）： 82 .
CHENG C ， LAU J E ， EARL M A . Use of atropine-diphenoxylate compared with hyoscyamine to decrease rates of irinotecan-related cholinergic syndrome [J ] . J Community Support Oncol ， 2015 ， 13 （ 1 ）： 3 - 7 .
0
Views
17
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.